ArticleAntimicrobial agents and chemotherapy2011
Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 61 citations in OpenAlex.
- Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotesBlood advances · 2019Trial
- A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Experimental Models to Study the Pathogenesis and Treatment of Mucormycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Miltefosine: A Repurposing Drug against Mucorales Pathogens.Journal of fungi (Basel, Switzerland) · 2023Article
- Characterization of the Sterol 24-C-Methyltransferase Genes Reveals a Network of Alternative Sterol Biosynthetic Pathways inMicrobiology spectrum · 2023Article
- Potential additional effects of iron chelators on antimicrobial- impregnated central venous catheters.Frontiers in microbiology · 2023Article
- Review
- Cutaneous and Pulmonary Mucormycosis in Rag1- and Il2rg-deficient Rats.Comparative medicine · 2020Article
- Mucormycosis of the Central Nervous System.Journal of fungi (Basel, Switzerland) · 2019Review
- Animal Models to Study Mucormycosis.Journal of fungi (Basel, Switzerland) · 2019Review
- In Vitro and In Vivo Evaluation of Voriconazole-Containing Antifungal Combinations against Mucorales Using aJournal of fungi (Basel, Switzerland) · 2019Article
- Animal Models of Aspergillosis.Comparative medicine · 2018Review
- Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model.Virulence · 2017Article
- Rodent Models of Invasive Aspergillosis due toFrontiers in microbiology · 2017Review
- Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin.Antimicrobial agents and chemotherapy · 2016Article
- Iron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies.Microbiology (Reading, England) · 2016Review
- Management of iron overload in the Canadian hematology/oncology population: Implications for nursing practice.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2016Article
- Article
- Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm.Antimicrobial agents and chemotherapy · 2015Article
- Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis. We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis. Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and to a lesser extent with aspergillosis. Continued investigation into the use of triple therapy against mucormycosis and aspergillosis is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.